Related Experiment Video

Updated: Jul 4, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Tirapazamine sensitises hypoxic homologous recombination-proficient NSCLC to PARP inhibition

Yanyan Jiang1,2, Nuria Vilaplana Lopera3, Hala Estephan3

  • 1Department of Oncology, University of Oxford, Oxford, UK. yanyan.jiang@well.ox.ac.uk.

Cell Death Discovery
|July 2, 2026
PubMed

Insights

Combining hypoxia-activated tirapazamine (TPZ) with PARP inhibitors (PARPi) like talazoparib shows promise for treating HR-proficient cancers. This strategy enhances DNA damage and cytotoxicity, particularly in hypoxic tumors.

Area of Science:

  • Oncology
  • Cancer Biology
  • Drug Development

Background:

  • PARP inhibitors (PARPi) are effective in homologous recombination (HR)-deficient tumors but limited in HR-proficient cancers.
  • Hypoxia suppresses HR, but insufficient DNA damage limits PARPi sensitization in HR-proficient cells.
  • Hypoxia-selective DNA damage is hypothesized to enhance PARPi efficacy in HR-proficient cancers.

Purpose of the Study:

  • To investigate the synergistic effect of tirapazamine (TPZ) and talazoparib in HR-proficient non-small cell lung cancer (NSCLC).
  • To determine the role of hypoxia in enhancing the efficacy of the TPZ-talazoparib combination.
  • To explore the mechanistic basis of synergy, focusing on DNA double-strand breaks (DSBs) and replication stress.

Main Methods:

  • In vitro cytotoxicity assays of TPZ and talazoparib in HR-proficient NSCLC cells under normoxia and hypoxia.
  • Assessment of DNA double-strand breaks (DSBs) and replication stress induction.
  • Inhibition of spheroid growth using the TPZ-talazoparib combination in hypoxic NSCLC spheroids.
  • Tumor growth suppression evaluation in subcutaneous xenografts of NSCLC models with varying hypoxia levels.

Main Results:

  • TPZ and talazoparib synergize to induce cytotoxicity in HR-proficient NSCLC cells, with enhanced activity under hypoxia.
  • The combination increases DNA double-strand breaks (DSBs) and replication stress, which persist in hypoxia.
  • TPZ-talazoparib significantly inhibited spheroid growth in hypoxic NSCLC spheroids.
  • Tumor growth was suppressed in highly hypoxic xenografts (A549, CORL105) but not in less hypoxic tumors (Calu-3, H3122).

Conclusions:

  • Hypoxia-targeted DNA-damaging agents like TPZ can expand PARPi utility to HR-proficient cancers.
  • The combination of TPZ and talazoparib demonstrates therapeutic potential in hypoxic, HR-proficient NSCLC.
  • Hypoxia is a critical factor enhancing the efficacy of this combination therapy.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...